We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+13.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$25B
AUM Growth
+$2.35B
Cap. Flow
+$638M
Cap. Flow %
2.55%
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$358M
2
PRLD icon
Prelude Therapeutics
PRLD
+$286M
3
KYMR icon
Kymera Therapeutics
KYMR
+$59.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$55.5M
5
NRIX icon
Nurix Therapeutics
NRIX
+$45.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$94.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.6M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$21.6M
4
INSM icon
Insmed
INSM
+$21.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.35%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
26
Nurix Therapeutics
NRIX
$2.44B
$62.5M 0.25%
+1,788,921
New +$45.1M
ALLK
27
DELISTED
Allakos
ALLK
$56.9M 0.23%
698,469
-37,000
-5% -$3M
ADCT icon
28
ADC Therapeutics
ADCT
$139M
$55.7M 0.22%
1,687,500
– –
RYTM icon
29
Rhythm Pharmaceuticals
RYTM
$7.35B
$53.5M 0.21%
2,471,155
-228,900
-8% -$5.25M
HZNP
30
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$51.8M 0.21%
666,500
+466,500
+233% +$32.1M
GBT
31
DELISTED
Global Blood Therapeutics, Inc.
GBT
$50.7M 0.2%
920,375
+873,375
+1,858% +$55.5M
ADAP
32
DELISTED
Adaptimmune Therapeutics
ADAP
$50.5M 0.2%
6,330,354
-344,827
-5% -$3.02M
BCEL
33
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$49.4M 0.2%
3,532,760
– –
CCXI
34
DELISTED
ChemoCentryx, Inc.
CCXI
$49.3M 0.2%
899,821
-45,400
-5% -$2.44M
NGNE icon
35
Neurogene
NGNE
$648M
$45.9M 0.18%
191,087
+21,200
+12% +$5.14M
BCRX icon
36
BioCryst Pharmaceuticals
BCRX
$2.43B
$43.6M 0.17%
12,695,818
-1,070,587
-8% -$4.59M
KNSA icon
37
Kiniksa Pharmaceuticals
KNSA
$6.12B
$42.9M 0.17%
2,799,577
– –
KRYS icon
38
Krystal Biotech
KRYS
$10.6B
$33.4M 0.13%
775,192
-42,439
-5% -$1.84M
PACB icon
39
Pacific Biosciences
PACB
$432M
$32.1M 0.13%
+3,250,000
New +$18.7M
PTGX icon
40
Protagonist Therapeutics
PTGX
$8.58B
$31.2M 0.12%
1,596,198
-315,248
-16% -$5.92M
SYRE icon
41
Spyre Therapeutics
SYRE
$8.25B
$31.1M 0.12%
175,184
– –
ALT icon
42
Altimmune
ALT
$580M
$29.1M 0.12%
2,206,955
+99,355
+5% +$1.99M
APLS
43
DELISTED
Apellis Pharmaceuticals
APLS
$27M 0.11%
896,551
– –
ASMB icon
44
Assembly Biosciences
ASMB
$494M
$25.3M 0.1%
128,452
-16
-0% -$4.03K
DBVT
45
DBV Technologies
DBVT
$799M
$25.3M 0.1%
1,461,426
– –
MRUS
46
DELISTED
Merus
MRUS
$24.4M 0.1%
2,037,469
– –
AUPH icon
47
Aurinia Pharmaceuticals
AUPH
$1.92B
$23.8M 0.1%
1,618,029
-83,900
-5% -$1.22M
CBAY
48
DELISTED
Cymabay Therapeutics
CBAY
$23.5M 0.09%
3,252,542
+1,729,750
+114% +$9.25M
ALKS icon
49
Alkermes
ALKS
$8.08B
$22.5M 0.09%
1,359,001
+114,257
+9% +$2.08M
FLGT icon
50
Fulgent Genetics
FLGT
$558M
$21.9M 0.09%
546,189
-23,255
-4% -$728K
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, Baker Bros. Advisors held 126 positions worth $25B, up 10% from $22.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2020 filing shows 11 new, 17 increased, 63 reduced and 6 closed positions. Its largest new stake was Prelude Therapeutics: 10,118,636 shares worth $305M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2020 buy was Prelude Therapeutics: 10,118,636 shares worth $305M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q3 2020, an estimated $358M increase.
  • Baker Bros. Advisors's biggest Q3 2020 reduction was Neurocrine Biosciences, cutting an estimated $26.6M.
  • Baker Bros. Advisors fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $94.5M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $25B portfolio in Q3 2020.
  • Baker Bros. Advisors opened 11 new positions and closed 6 in Q3 2020.
  • Baker Bros. Advisors's portfolio value rose 10% quarter-over-quarter to $25B.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.